'Monoclonal antibodies - dawn of a new era' seminar

24 September 2013

14.30-18.00 GMT

Bird & Bird London

MAbs have for a long time been the promise for cancer therapy and other therapeutical applications where traditional pharmaceuticals have not provided the solution. Now they  have emerged as the state of the art therapy for the future. Due to their very nature, they pose different questions and issues than small molecule drugs that are common in the marketplace today.
This seminar will deal with the protection of the investment in MAbs from a regulatory and IP perspective, from the very inception until market launch. It will offer both a practical and a strategic approach for tackling these issues.
If you wish to submit a question ahead of the seminar, for our speakers to answer, please indicate this over email. We will endeavour to answer all questions.

CPD accreditation
This seminar is SRA accredited with 3 CPD hours.

This event is free of charge however registration is required. If you wish to attend please use the email contact below.

Would you like to attend?

The programme

Coffee and registration


Welcome and introduction

Wouter Pors, Partner, The Netherlands

15.05 - 15.35
MAbs - How to protect them using patents and SPCs
Michael Alt, Partner, Germany
15.35 - 16.05
Infringement issues relating to MAbs
Trevor Cook, Partner, United Kingdom
16.05 - 16.35
New US biosimilar guidelines - compared to the EU
Liz Fuller, Consultant, UK
16.35 - 17.05
Update on the use of human cells and tissues, and on the Advanced Therapy Medicinal Products in Europe
Marc Martens, Partner, Belgium
17.05 - 17.35
An industry perspective
Frank Landolt, IP and Legal Counsel, Ablynx
17.35 - 18:00
Ask the experts - Q&A with the Panel

Contact / Registration

For further information or to book please contact events@twobirds.com